HRTX Mid-Q1 '19 Update


HRTX announced exciting new results in early January that 90% of patients receiving HTX-011 and over-the-counter pain meds did not need opioids for post-op pain through 72 hours after surgery, compared to 51%, 40%, and 22% of patients receiving HTX-011, bupivacaine, or placebo alone. The company's U.S. marketing application seeking approval for HTX-011 plus meloxicam is currently under FDA review with an action date of April 30.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon